Modalis Therapeutics
4883.TTSE GROWTHPharmaceutical
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | ¥41m | ¥1m | ¥342m |
| Operating income | −¥2.3bn | −¥1.5bn | −¥2.5bn | −¥2.1bn | −¥1.3bn | — |
| Ordinary income | −¥2.2bn | −¥1.4bn | −¥2.4bn | −¥2.1bn | −¥1.3bn | −¥468m |
| Total assets | ¥2.6bn | ¥3.5bn | ¥1.8bn | ¥3.0bn | ¥5.9bn | ¥6.2bn |
| Net assets / equity | ¥2.6bn | ¥3.4bn | ¥1.4bn | ¥2.9bn | ¥5.4bn | ¥6.2bn |
| EPS (basic) | ¥-29.11 | ¥-31.24 | ¥-77.59 | ¥-88.88 | ¥-27.58 | ¥-17.79 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 15
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 62 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 172 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 62 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 174 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 62 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 38 figures · EDINET |
| 2023-01-01 → 2023-12-31 | AnnualAmended | 175 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 175 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 40 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 64 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 38 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 183 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2Amended | 65 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 40 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 65 figures · EDINET |
8 more reports are still being processed.